All In Biotech

Drug Trial Radar · NCT00395161

The CRISIS Prevention Study

The Critical Illness Stress-induced Immune Suppression Prevention Trial

Last checked: Nov 19, 2026Latest source record: Apr 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 293 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

293

Actual

Start

Apr 2007

Primary completion

Nov 2009

Study completion Nov 2009

Sponsor

Lead sponsor
Michael DeanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Seattle Children's Hospital; Children's Hospital Los Angeles; Arkansas Children's Hospital Research Institute; Children's Hospital of Michigan; University of Pittsburgh; Children's National Research Institute; University of California, Los Angeles; Harborview Injury Prevention and Research Center
First posted
Nov 2, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 12 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Despite strict hand washing, sterile technique, and antibiotic-coated catheters, nosocomial infection and sepsis remain the leading acquired causes of morbidity and mortality in critically ill children. Subsequent use of antibiotics to treat nosocomial infection and sepsis is considered a major attributable factor in the rise of antibiotic-resistant organisms in this population of children. This study will use a double-blind, randomized, controlled trial design to test the hypothesis that daily prophylaxis with metoclopramide, zinc, selenium and glutamine will reduce nosocomial infection and sepsis in critically ill children.

Conditions

  • Sepsis

Interventions

  • MetoclopramideDrug

    0.2 mg/kg/dose IV every 12 hours

  • ZincDrug

    one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)

  • GlutamineDietary supplement

    one enteral dose daily of glutamine 0.3 gm/kg/day

  • SeleniumDrug

    one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children \> 13 years)

  • salineOther

    equivalent volume of intravenous saline

  • sterile waterOther

    equivalent volume of sterile water

  • seleniumOther

    equivalent volume of sterile water

  • whey-proteinDietary supplement

    one enteral dose daily of whey-protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Primary Endpoint of This Study is the Median Time Between Admission to the PICU and Occurrence of Nosocomial Infection or Clinical Sepsis in PICU Patients Who Have Endotracheal Tubes, Central Venous Catheters, or Urinary Catheters.Time frame: 48 hours after admission until 5 days after discharged from the PICU

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Childrens Hospital of Los Angeles

    Los Angeles, California

  • University of California Los Angeles Medical Center

    Los Angeles, California

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Hospital of Michigan

    Detroit, Michigan

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.